These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9834828)

  • 21. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
    Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
    Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
    Perez AT; Domenech GH; Frankel C; Vogel CL
    Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of piperazinedione in metastatic sarcoma.
    Presant CA; Bartolucci AA
    Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
    Casper ES; Schwartz GK; Sugarman A; Leung D; Brennan MF
    J Clin Oncol; 1997 May; 15(5):2111-7. PubMed ID: 9164225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
    Borden EC; Amato DA; Edmonson JH; Ritch PS; Shiraki M
    Cancer; 1990 Sep; 66(5):862-7. PubMed ID: 2201431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation.
    McMenemin R; Macdonald G; Moffat L; Bissett D
    Invest New Drugs; 2002 Aug; 20(3):331-7. PubMed ID: 12201496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
    Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.
    Blay JY; Judson I; Rodenhuis S; Hermans C; Smith M; van Glabbeke M; Verweij J
    Anticancer Drugs; 1999 Nov; 10(10):873-7. PubMed ID: 10630354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
    Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
    Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
    De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
    Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of Doxil and vinorelbine in metastatic breast cancer.
    Burstein HJ; Ramirez MJ; Petros WP; Clarke KD; Warmuth MA; Marcom PK; Matulonis UA; Parker LM; Harris LN; Winer EP
    Ann Oncol; 1999 Sep; 10(9):1113-6. PubMed ID: 10572612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.